Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
dementia with Lewy bodies treatment
market4 mentionslast seen Oct 29, 2026
Treatment of DLB, a form of dementia.
Relationships 2
Relationship
neflamapimodapplies todementia with Lewy bodies treatment
99% confidence3 supporting mentions
Either name opens that entity’s relationships.
Sources 3
- filingSEC EDGAROct 29, 2026CervoMed Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
neflamapimod as a potential treatment for dementia with Lewy bodies (DLB)
- filingSEC EDGAROct 13, 2026CervoMed Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies (DLB)
- filingSEC EDGARSep 28, 2026CervoMed Inc. 8-K: Item 7.01: Regulation FD Disclosure; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB